oxybutynin chloride


Also found in: Dictionary.

oxybutynin chloride

[ok′sibo̅o̅′tinin]
an anticholinergic.
indication It is prescribed in the treatment of neurogenic bladder.
contraindications Glaucoma, obstruction of the GI or urinary tract, ulcerative colitis, paralytic ileus, toxic megacolon, or known hypersensitivity to this drug or to other anticholinergics prohibits its use.
adverse effects Among the more serious adverse effects are decreased sweating, urinary retention, blurred vision, tachycardia, and severe allergic reactions.
References in periodicals archive ?
The pharmacokinetics of intravesical and oral oxybutynin chloride.
market sales for Oxybutynin Chloride Extended-Release Tablets, USP, which is used in the treatment of overactive bladder, were approximately $156 million for the twelve months ended August 31, 2016.
Human health company ACETO (NasdaqGS:ACET) stated on Monday that it plans to introduce Oxybutynin Chloride Extended-Release Tablets, USP in the market .
Key Words: Application drying time, overactive bladder, oxybutynin chloride topical gel.
Oxybutynin chloride for geriatric urinary dysfunction: a double-blind placebo-controlled study [see comments).
Drugs such as oxybutynin chloride (Ditropan[R] also may reduce bladder spasms.
Tenders are invited for Tablet Oxybutynin Chloride 5 Mg.
The Kremers Urban portfolio also provides several difficult-to-manufacture and extended-release products that require complex drug development technology and manufacturing processes including: atorvastatin calcium tablets, hydrocodone polistirex and chlorpheniramine polistirex Pennkinetic extended-release suspension CIII, methylphenidate HCI extended-release capsules CD CII, nifedipine extended-release tablets USE nitroglycerin transdermal systems, omeprazole delayed-release capsules USE oxybutynin chloride extended-release tablets USE pantoprazole sodium delayed-release tablets USE tacrolimus capsules, verapamil hydrochloride extended-release (PM) capsules, and several other generic products.
Effects of oxybutynin chloride topical gel on health-related quality of life in adults with overactive bladder: A randomized, double-blind, placebo-controlled study.
The US Food and Drug Administration has accepted for filing a New Drug Application (NDA) for oxybutynin chloride topical gel (OTG) from Watson Pharmaceuticals, Inc.
Prospective randomized controlled trial of extend-release oxybutynin chloride and tolterodine.
Among these drugs are oxybutynin chloride and propantheline bromide.